Cancer-associated Fibroblast (CAF) Targeting Dual CAR Development Service for Solid Tumor Targeting

Q: How do you validate the efficacy and safety of dual CARs?

We perform comprehensive in vitro functional assays, including cytotoxicity, CAF clearance, dual-target activation, and 3D spheroid penetration. An optional in vivo evaluation in CAF-rich xenograft or PDX models provides preclinical efficacy and safety data.

Online Inquiry

Background Service What We Can Offer Workflow Highlights Data Support FAQs Contact

Creative Biolabs' CAF-Targeting Dual CAR Development Service is designed to address limited immune cell infiltration, dense stromal architecture, and suppressive signaling within solid tumors. By engineering CAR-T cells to simultaneously recognize tumor antigens and cancer-associated fibroblasts, this platform enables active remodeling of the extracellular matrix and improved access to malignant cells. Through integrated dual-receptor design and microenvironment-modulating strategies, researchers can enhance cytotoxic activity, increase intra-tumoral persistence, and advance next-generation cell therapies for challenging solid tumor indications.

Introduction

Cancer-associated fibroblasts contribute to extracellular matrix (ECM) deposition, immune suppression, and tumor progression. Dual-target CAR strategies that include both tumor antigens and cancer-associated fibroblasts (CAFs) markers have demonstrated improved tumor infiltration and reduced immune escape in published preclinical research, supporting their growing relevance in solid tumor immunotherapy.

How Creative Biolabs' CAF Targeting Dual CAR Development Service Can Assist Your Project

Creative Biolabs provides a comprehensive, end-to-end development framework to help you design, evaluate, and optimize dual CAR-T therapies capable of simultaneously targeting cancer cells and CAFs. By addressing tumor cell eradication and tumor microenvironment remodeling in parallel, this service contributes to enhanced infiltration, reduced stromal resistance, and improved tumor regression outcomes. Our dual-targeting strategies are customizable based on tumor antigen expression profiles, CAF phenotype, microenvironment composition, desired cytokine support, and safety parameters.

Discover How We Can Help - Request a Consultation.

What we can offer

Target Selection Strategy

Category	Key Advantages
CAF-Specific Targets	Minimal impact on non-tumor tissues
Tumor Cell Targets	Enhanced precise elimination of tumor cells

Dual CAR Design

Mode	Design Structure	Features
Tandem CAR	Single vector containing two scFvs in tandem	Simplified construction, but signals cannot be regulated independently
Bispecific Dual CAR	Two independent CAR chains	Activation logic can be optimized separately; high flexibility
Logic-Gated CAR (AND / OR / NOT)	Co-stimulatory domain expression strategy	Customizable control over safety and activation

Our Workflow

The process begins with establishing target antigen priorities, selecting a CAF marker, and choosing an effector cell type.

Workflow of CAF Targeting Dual CAR Development. (Creative Biolabs Original)

Unique Features

Comprehensive in vitro validation: cytotoxicity, CAF clearance, dual-target activation, and 3D spheroid/organoid penetration assays.
Robust quality control and documentation, including construct verification, functional validation reports, and preclinical study summaries.
Support for both CAR-T (autologous or allogeneic) and CAR-NK (primary, or iPSC-derived) platforms.
End-to-end consultation and optimization to balance efficacy, safety, and persistence for studies.

Data Support

This research addresses a critical obstacle in treating solid tumors: the protective barrier created by CAFs. Scientists developed a universal CAR-T platform that employs bispecific adapters to simultaneously direct T cells against both tumor cells and CAFs. This innovative approach markedly improved tumor regression by enhancing T cell activation, infiltration, and distribution throughout the tumor microenvironment.

Engineering of a bispecific car against cancer-associated fibroblasts. (OA Literature) Fig.1 Development of a dual car for targeting cancer-associated fibroblasts.¹

FAQs

Can I target any combination of tumor antigen and CAF marker?

Yes. We support a wide range of tumor antigens and CAF markers. Our team can guide you in selecting the optimal combination based on your tumor type and desired dual CAR logic.

Is the service compatible with both CAR-T and CAR-NK platforms?

Absolutely. We engineer dual CAR constructs for autologous or allogeneic T cells as well as primary NK, or iPSC-derived NK cells, ensuring flexibility to meet your therapeutic strategy.

Can you include additional functional modules, such as cytokine support or ECM remodeling enzymes?

Yes. Optional modules like IL-15 or IL-12 cytokine support and ECM-modifying enzymes can be integrated to enhance TME penetration and CAR persistence. Custom combinations are available upon consultation.

How do you validate the efficacy and safety of dual CARs?

We perform comprehensive in vitro functional assays, including cytotoxicity, CAF clearance, dual-target activation, and 3D spheroid penetration. An optional in vivo evaluation in CAF-rich xenograft or PDX models provides preclinical efficacy and safety data.

Partner with Us

Creative Biolabs offers a comprehensive CAF Targeting Dual CAR Development Service designed to simultaneously target tumor cells and cancer-associated fibroblasts. Our end-to-end solutions include dual CAR design, construct engineering, functional in vitro validation, optional in vivo preclinical evaluation, and optimization of CAR efficacy, safety, and persistence. For detailed information on our CAF-targeting dual CAR services or to discuss your specific project needs, please reach out to our expert team. We provide tailored consultation, project planning, and technical guidance to accelerate your therapeutic development.

Reference

Huang, Bo et al. "Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts." Frontiers in immunology vol. 16 1539265. 17 Feb. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1539265

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.